Özlem GÜNEYSEL, Sait KARAKURT, Serpil PİRMİT

Plasma d-dimer levels increase with the severity of community acquired pneumonia

Bu çalışmanın amacı, plazma D-dimer (D-d) düzeyi ile toplum kökenli pnömoni (TKP) arasındaki ilişkiyi araştırmaktır. Bu çalışma, prospeküf kontrollü olarak yapılmıştır. ATS 2001 TKP Rehberi kullanılarak hastalar iki gruba [hafif (n= 37) ve ağır pnömoni (n= 14)1 ayrıldı. Kontrol grubu da dahil edilerek tüm gruplarda plazma D-d düzeyi ELISA yöntemi ile araştırıldı. Plazma D-d düzeyleri ağır pnömoni grubunda 2438 ± 2158 ng/mL, hafif pnömoni grubunda 912.6 ± 512.6 ng/mL ve kontrol grubunda 387 ± 99.56 ng/mL olarak bulundu. Kontrol grubuyla karşılaştırıldığında hafif (p< 0.05) ve ağır (p< 0.001) pnömoni gruplarında plazma D-d düzeylerinin anlamlı arttığı gözlendi. Ayrıca hasta grupları kendi aralarında karşılaştırıldığında, hastalığın şiddetiyle orantılı olarak plazma D-d düzeylerinin de arttığı bulunmuştur. TKP'li hastalarda plazma D-d düzeyleri yükselmektedir. D-d düzeyleri hastalığın şiddetiyle orantılı olarak artmaktadır.

Plazma d-dimer düzeyi toplum kökenli pnömoninin ağırlığıyla orantılı olarak artmaktadır.

The aim of this study is to investigate the relationship of the plasma D-Dimer (D-d) level and the severity of the pneumonia in patients who have not any disease that may increase the D-d level, but pneumonia. This is prospective controlled study. Using the ATS 2001 Community Acquired Pneumonia (CAP) Guideline we divided the patients into two groups [severe (n= 14) and non-severe (n= 37) CAP] and looked for any significant difference in D-d tevels with ELISA method among the patients groups and control group. Plasma D-d levels were 2438 ± 2158 ng/mL in severe CAP group, 912.6 ± 512.6 ng/mL in non-severe CAP group and 387 ± 99.56 ng/mL in the control group. Patients with non-severe CAP and those with severe CAP group both showed an increase in plasma levels of D-d compared to control group (p< 0.05, p< 0.001, respectively). We also found that the severe CAP group had increased in plasma levels of D-d compared to the non-severe CAP group (p< 0.001). Plasma D-d level increases significantly in patients with CAP compared to control group. Plasma D-d levels increases significantly with the severity of the CAP.

PDF

___

1. Mavromatis BH, Kessler CM. D-dimer testing: The role of the clinical laboratory in the diagnosis of pulmonary embolism. J Clin Pathol 2001; 54: 664-8.
2. Weiner SG, Burstein JL. Nonspecific tests for pulmonary embolism. Emerg Med Clin North Am 2001; 19: 943-55.
3. Kutinsky I, Blakely S, Roche V. Normal D-dimer levels in patients with pulmonary embolism. Arch Intern Med 1999; 159: 1569-72.
4. Freyburger G, Trillaud H, Labrouche S, et al. D-dimer strategy in thrombosis exclusion. Thromb Haemost 1998; 79: 32-7.
5. Crippa L, D'Angelo VS, Tomassini L, et al. The utility and cost-effectiveness of D-dimer measurements in the diagnosis of deep vein thrombosis. Haematologica 1997; 82: 446-51.
6. Goldstein MN, Kollef MH, Ward S, Gage BF. The impact of the introduction of a rapid D-dimer assay on the diagnostic evaluation of suspected pulmonary embolism. Arch Intern Med 2001; 161: 567-71.
7. Lennox AF, Nicolaides AN. Rapid D-dimer testing as an adjunct to clinical findings in excluding pulmonary embolism. Thorax 1999; 54(Suppl 2): 533-6.
8. Bovill EG, Tracy RP. Fibrin(ogen) degradation products. In: Beuller E, Lichman MA, Coller BS, Kipps TJ (eds). William's Haematology. 5th ed. New York: Mc Graw-Hill,1995: 104-5.
9. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987; 317: 1361-5.
10. Bayes-Genis A, Mateo J, Santalo M, et al. D-dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am Heart J 2000; 140: 379-84.
11. Chabloz P, Reber G, Boehlen F. TAFI antigen and d-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001; 115: 150-2.
12. Oya M, Akiyama Y, Yanagida T, et al. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today 1998; 28: 373-8.
13. Taguchi 0, Gabazza EC, Yasui H, et al. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997; 52: 563-5.
14. Francis CW, Conanghan G, Scott WL, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987; 75:1170-7.
15. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease. Circulation 2001; 103:2323-7.
16. Lee VL, Ewald AG, Mckenzie CR, Eisenberg PR. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vase Biol 1997; 17: 628-33.
17. Wilde JT, Kitchen S, Kinsey S, et al. Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. Br J Haematol 1989; 71: 65-9.
18. Miller A. A fresh look at a D-dimer in suspected pulmonary embolism. Thorax 1998; 53: 821-2.
19. Legere BM, Dweik RA, Arroliga AC. Venous thromboembolism in the intensive care unit. Clin Chest Med 1999;20: 367-84.
20. Becker DM, Philbrick JT, Bachhuber TL, Humphries JE. D-dimer testing and acute venous thromboembolism. Arch Intern Med 1996; 156: 939-46.
21. Pieper CF, Rao KMK, Currie MS, et al. Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. J Gerontol 2000; 55: 649-57.
22. Levison ME. Pneumonia, including necrotizing pulmonary infections (lung abcess). In: Fauci A, Braunwald E, Isselbacher KJ, Wilson JD, et al (eds). Harrison's Principles of Internal Medicine. Vol 2. 14th ed. New York: Mc Graw-Hill, 1998: 1437-45.
23. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guide- lines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
24. Quick G, Eisenberg P. Bedside measurement of D-dimer in the identification of bacteremia in the emergency department. J Emerg Med 2000; 19:217-23.
25. Deitcher SR, Eisenberg PR. Elevated concentrations of cross-linked fibrin degradation products in plasma. Chest 1993; 103: 1107-12.
26. Kobzik L The lung. In: Robbins SL, Cotran RS, Kumar V, Collins T (eds). Robbins Pathologic Basis of Disease. 6 th ed. WB. Saunders, 1999: 697-755.
27. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
28. Raimondi P, Bongard O, de Moerloose P, et al. D-dimer plasma concentration in various clinical conditions: implification for the use of this test in the diagnostic approach of venous thromboembolism. Thromb Res 1993; 69: 125-30.
29. Castro DJ, Perez-Rodriguez E, Montaner L, et al. Dignostic value of D-dimer in pulmonary embolism and pneumonia. Respiration 2001; 68: 371-5.
30. Shilon Y, Shirit AB, Rudensky B, et al. A rapid quantitative D-dimer assay at admission correlates with the severity of community acquired pneumonia. Blood Coagul Fibrinolysis 2003; 14: 745-8.